1 2 3 4 5		E-FILED 4/3/2017 12:28:51 PM Clerk of Court Superior Court of CA, County of Santa Clara 16CV295357 Reviewed By:R. Walker	
6			
7			
8	SUPERIOR COURT OF CALIFORNIA		
9	COUNTY OF SANTA CLARA		
10			
11	KEITH ANDERSON,	Case No.: 16-CV-295357	
12	Plaintiff,		
13	VS.	ORDER AFTER HEARING ON MARCH 30, 2017	
14			
15	ALEXZA PHARMACEUTICALS, INC., ET	Plaintiffs' Motion for Final Approval of Class Action Settlement	
16	AL.,		
17	Defendants.		
18			
19		hearing on Thursday, March 30, 2017 at 3:00	
20	p.m. in Department 19 (Complex Civil Litigation		
21	The Court reviewed and considered the written submission of all parties and issued a tentative		
22	ruling on March 29, 2017. The Court has also considered the argument presented by the		
23	parties at the hearing. The matter having now been submitted, the Court rules as follows:		
24	This putative shareholder class action arises from the agreed sale of Alexza		
25	Pharmaceuticals, Inc. to Grupo Ferrer Internacional, S.A. and its subsidiary. (Complaint, ¶ 1.)		
26	Before the Court is plaintiffs' motion for final approval of a settlement.		
27	111		
28	111		
	Keith Anderson v. Alexza Pharmaceuticals, Inc., et al.	16 CV 205357	

Superior Court of California, County of Santa Clara, Case No. 16-CV-295357 Order After Hearing on March 30, 2017 [Plaintiffs' Motion for Final Approval of Class Action Settlement]

11

Pursuant to the settlement, Alexza made certain supplemental disclosures in connection with the merger in exchange for a release of claims. There will be no monetary recovery to the class, although defendants have agreed not to oppose plaintiff's request for attorney fees.

While settlements with this structure were once regularly approved, recent decisions have questioned this practice. *In re Trulia, Inc. Stockholder Litigation* (Del. Ch. 2016) 129 A.3d 884 explains in detail the issues with these "disclosure settlements," and held that

practitioners should expect that disclosure settlements are likely to be met with continued disfavor in the future *unless the supplemental disclosures address a plainly material misrepresentation or omission*, and the subject matter of the proposed release is narrowly circumscribed to encompass nothing more than disclosure claims and fiduciary duty claims concerning the sale process, *if the record shows that such claims have been investigated sufficiently*.

(*Id.* at p. 898, italics added.) *Trulia* was endorsed by Judge Posner of the United States Court of Appeals for the Seventh Circuit in a published opinion, *In re Walgreen Co. Stockholder Litigation* (7th Cir. 2016) 832 F.3d 718. The Court agrees with the reasoning of these cases and adopts the standard that they establish for these types of settlements.

Plaintiffs' original motion for preliminary approval did not address the materiality of the supplemental disclosures in light of these authorities. The Court therefore continued the motion for supplemental briefing, which plaintiffs filed on December 9, 2016. In that briefing, plaintiffs represented that "as part of the Supplemental Disclosures, Alexza revealed that the analysis of its financial advisor, Guggenheim, was limited to a *Liquidation Analysis*" prepared by Alexza management. (At p. 3.) "Significantly, Plaintiffs' expert explicitly set forth his opinion that this disclosure was material because it informed shareholders that 'Guggenheim did not conduct any independent financial analysis but rather simply adopted management's potentially conflicted views of value for every asset and every liability comprising the Liquidation Analysis.'" (At pp. 3-4.) Relying on plaintiffs' characterization, the Court issued its tentative ruling preliminarily approving the settlement, explaining in its analysis that plaintiffs' expert

Keith Anderson v. Alexza Pharmaceuticals, Inc., et al. Superior Court of California, County of Santa Clara, Case No. 16-CV-295357 Order After Hearing on March 30, 2017 [Plaintiffs' Motion for Final Approval of Class Action Settlement] opines that the Supplemental Disclosure made clear that the only financial analysis that was reviewed and considered by the fairness consultant, Guggenheim Securities, was the Liquidation Analysis prepared by Alexa's senior management and not Guggenheim. In other words, [the expert] is critical of Guggenheim for not performing any independent valuation analysis and simply relying on management's analysis which had the potential for conflicted views of value for every asset and liability.

1

2

3

4

5

10

11

12

13

14

15

- Plaintiffs did not raise any issues regarding the Court's description of the supplemental
 disclosures at the preliminary approval hearing. Since that hearing, certain statements on page
 30 of the original Schedule 14D-9, filed with the SEC on May 23, 2016, have come to the
 Court's attention. That original filing provided:
 - In arriving at its opinion, Guggenheim Securities did not perform or obtain any independent appraisal of the assets or liabilities ... of Alexza or the solvency or fair value of Alexza, nor was Guggenheim Securities furnished with any such appraisals. As noted above, Alexza's senior management prepared the Liquidation Analysis and provided it to Guggenheim Securities in connection with its opinion.
 - The original filing went on to provide three additional disclaimers emphasizing that Guggenheim did not independently evaluate Alexza's liquidation value, assets, or liabilities.
- It thus appears to the Court that its decision to preliminarily approve the settlement was
 based on an incorrect premise: that Guggenheim's complete reliance on the Liquidation
 Analysis prepared by management, without conducting any independent financial analysis, was
 disclosed for the first time in the Supplemental Disclosures.
- In addition, having performed its own comparison of the supplemental disclosures 20 provided in Amendment No. 2 to the 14D-9 to the original 14D-9, the Court is not convinced 21 22 that the other assertedly new disclosures discussed in plaintiffs' supplemental brief are plainly material. While the Liquidation Analysis itself was newly-disclosed, the analysis shows that 23 Alexa's liabilities far exceeded its assets under either the low or high projection, and the fact 24 that the Liquidation Analysis indicated a per share value of zero was already disclosed at page 25 31 of the original 14D-9. So too were the uncertainties regarding ADASUVE, discussed 26 throughout the original 14D-9. The conclusion that Alexa's assets exceeded its liabilities is 27 further highlighted by disclosures on page 29 of the original 14D-9, beginning, "if Alexza were 28

to satisfy all of its existing credit and other payment obligations, then Alexza's liquidity resources would likely be immediately depleted" The Court does not believe that the details of the Liquidation Analysis plainly and "significantly alter[ed] the 'total mix' of information made available" under these circumstances. (In re Trulia, Inc. Stockholder Litigation, supra, 129 A.3d at p. 899.)

Similarly, plaintiffs state in their supplemental brief that "[t]he Original 14D9 was silent on how ... warrant values were calculated despite their significant impact on the value of the Acquisition consideration." (At p. 5.) However, the drop in per share cash consideration that plaintiffs' expert attributes to the warrants was disclosed in the context of a discussion of the warrants at page 19 of the original 14D9. It was disclosed that Alexa's trading volatility reached a peak of 327% and "[g]iven this increase, the Black-Scholes value of Alexa's out-ofthe-money warrants increased to approximately \$3.7 million from approximately \$400,000," an obviously significant increase. Given these disclosures, the Court is not convinced that the additional details about how the warrant values were calculated were plainly material, either. 14

In the Court's view, the value of these new disclosures to shareholders was de minimis and does not justify the release they would provide under the settlement.

At the hearing on this matter, plaintiffs did not deny that it was disclosed in the original 14D-9 that the Liquidation Analysis was the only analysis Guggenheim considered. Instead, they relied entirely upon their argument that the disclosure of the content of the Liquidation Analysis was material. However, other than a brief reference to the "valuation spread" reflected therein, they did not explain why the details of the Liquidation Analysis were material or address the Court's analysis on this point set forth above. The Court remains unpersuaded 22 23 that these details were plainly material.

The motion for final approval of the settlement is accordingly DENIED. A case 24 management conference is hereby scheduled for May 26, 2017 at 10:00 a.m. in Department 25 26 19.

27 111

1

2

3

4

5

6

7

8

9

10

11

12

13

15

16

17

18

19

20

21

28 111

> Keith Anderson v. Alexza Pharmaceuticals, Inc., et al. Superior Court of California, County of Santa Clara, Case No. 16-CV-295357 Order After Hearing on March 30, 2017 [Plaintiffs' Motion for Final Approval of Class Action Settlement]

IT IS SO ORDERED.	
Dated: April 3, 2017	Peter H. Kirwan
Julea: 11pin 2, 2011	Honorable Peter H. Kirwan Judge of the Superior Court
	Judge of the Superior Court
X.	

Superior Court of California, County of Santa Clara, Case No. 16-CV-295357 Order After Hearing on March 30, 2017 [Plaintiffs' Motion for Final Approval of Class Action Settlement]

Ш